Estimation of the level of endothelial factor of vascular growth and monocytic chemoattractant in children cerebral palsy
https://doi.org/10.21626/vestnik/2021-3/04
Abstract
Objective. The aim of this article is to assess the role of vascular endothelial growth factor and monocytic chemoattractant in the development of cerebral palsy in children.
Materials and methods. Examination of 77 children with different clinical forms of infantile cerebral palsy in the age group from 1 to 16 years was carried out. The content of monocyte chemoattractant (MCP) and vascular growth factor (VEGF) was determined in different forms of cerebral palsy. The obtained data were processed statistically.
Results. The analysis of the obtained data revealed a significant increase in the indicators of monocytic chemoattractant and vascular growth factor in children with infantile cerebral palsy compared with healthy children. There were no significant differences between the indicators of MCP and VEGF in children with cerebral palsy and comorbid pathology and children with cerebral palsy without concomitant pathology.
Conclusion. The authors of the presented analysis conclude that the determination of monocytic chemoattractant and vascular growth factor has a high diagnostic value for identifying a predisposition to the development of cerebral palsy. Timely detection of an increase in the level of these factors provides a broader prospective for early diagnosis of the disease and for the early implementation of rehabilitation measures accordingly.
About the Authors
Zulfiya M. Nurzhanova
Astrakhan Regional Social and Rehabilitation Center “Rus”
Russian Federation
Russian Federation
Head of the Department of Kinesiotherapy
Anna A. Shilova
Astrakhan State Medical University
Russian Federation
Russian Federation
Cand. Sci. (Med.), Assistant of the Department of Faculty Pediatrics
Ol'ga A. Bashkina
Astrakhan State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Faculty Pediatrics
Marina A. Samotrueva
Astrakhan State Medical University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology
References
1. Bashkina O.A, Nurzhanova Z.M., Shilova A.A., Belan E., Samotruyeva M.A. Search for biological markers of disregulative disturbances in children's cerebral paralysis. Astrakhanskiy meditsinskiy zhurnal. 2020;15(1):36-48 (in Russ.). DOI: 10.17021/2020.15.1.36.48
2. Vlasov T.D., Nesterovich I.I., Shiman’ski D.A. Endothelial dysfunction: from the particular to the general. return to the "old paradigm"? Regional blood circulation and microcirculation. 2019;18(2):19-27 (in Russ.). DOI: 10.24884/1682-6655-2019-18-2-19-27
3. Ivanov A.N., Grechikhin A.A., Norkin I.A., Puchinyan D.M. Methods of endothelial dysfunction diagnosis. Regional blood circulation and microcirculation. 2014;13(4):4-11 (in Russ.)
4. Savenkova N.D., Dzhumagaziyev A.A., Bezrukova D.A., Rayskiy D.V. Markers of transient and persistent bronchial obstruction syndrome phenotype in children. Doktor.Ru. 2019;5(160):11-14 (in Russ.). DOI: 10.31550/1727-2378-2019-160-5-11-14
5. Stepanova T.V. Ivanov A.N., Popykhova E.B., Lagutina D.D. Markers of endothelial dysfunction: pathogenetic role and diagnostic significance. Russian Clinical Laboratory Diagnostics Journal. 2019;64(1):34-41 (in Russ.). DOI: 10.18821/0869-2084-2019-64-1-34-41
6. Tkachenko E.S., Goleva O.P., Shcherbakov D.V., Khalikova A.R. Cerebral palsy: the state of knowledge of the problem (review). Mother and baby in Kuzbass. 2019;2(77):4-9 (in Russ.)
7. Fateyeva V.V., Vorob’yeva O.V. Cerebral markers of endothelial dysfunction in chronic brain ischemia. S.S. Korsakov Journal of neurology and psychiatry. 2017;117(4):107-111 (in Russ.). DOI: 10.17116/jnevro201711741107-111
8. Apte R.S., Chen D.S., Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248-1264. DOI: 10.1016/j.cell.2019.01.021
9. Chan S.J., Love C., Spector M., Cool S.M., Nurcombe V., Lo E.H. Endogenous regeneration: Engineering growth factors for stroke. Neurochem Int. 2017;(107):57-65. DOI: 10.1016/j.neuint.2017.03.024
10. Dommel S., Blüher M. Does C-C Motif Chemokine Ligand 2 (CCL2) Link Obesity to a Pro-Inflammatory State? Int J Mol Sci. 2021;22(3):1500. DOI: 10.3390/ijms22031500
11. Graham H.K., Rosenbaum P., Paneth N., Dan B., Lin J.P., Damiano D.L., Becher J.G., Gaebler-Spira D. et al. Cerebral palsy. Nat Rev Dis Primers. 2016;(2):15082. DOI: 10.1038/nrdp.2015.82
12. Krigger K.W. Cerebral Palsy: an overview. Am Fam Physician. 2006;73(1):91-100.
13. Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M., Mihu C., Istrate M., Moldovan I.M., Roman A.L. et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2): 455-467
14. Peach C.J., Mignone V.W., Arruda M.A., Alcobia D.C., Hill S.J., Kilpatrick L.E., Woolard J. Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. Int J Mol Sci. 2018;19(4):1264. DOI: 10.3390/ijms19041264
15. Rosenstein J.M., Krum J.M., Ruhrberg C. VEGF in the nervous system. Organogenesis. 2010;6(2):107-114. DOI: 10.4161/org.6.2.11687
16. Vitrikas K, Dalton H, Breish D. Cerebral Palsy: An Overview. Am Fam Physician. 2020;101(4):213-220.
17. Wu Y., Tang J., Chen Y., Huang Y. Social-Emotional Development and Associated Risk Factors in Chinese Toddlers with Cerebral Palsy. Neuropsychiatr Dis Treat. 2021;(17):2451-2463. DOI: 10.2147/NDT.S308138
Review
For citations:
Nurzhanova Z.M., Shilova A.A., Bashkina O.A., Samotrueva M.A. Estimation of the level of endothelial factor of vascular growth and monocytic chemoattractant in children cerebral palsy. Humans and their health. 2021;24(3):33-38. (In Russ.) https://doi.org/10.21626/vestnik/2021-3/04
Views:
334
Email this article 